GlassScriptPhysician profile
Najat S George
NPI 1649581471
$1,412.56
in general payments reported to CMS, 2019-2025
23 companies · $403 in 2025
The $403 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $91.79 · 2021: $182 · 2022: $84.61 · 2023: $363 · 2024: $140 · 2025: $403.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $228.95 | 2023 | Gvoke Hypopen |
| Abbott Laboratories | $183.08 | 2022-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $149.31 | 2019-2020 | |
| Shield Therapeutics INC | $138.17 | 2022-2025 | Accrufer |
| Exact Sciences Corporation | $131.86 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $89.66 | 2019-2021 | |
| Novo Nordisk INC | $66.93 | 2021 | |
| Agios Pharmaceuticals, INC. | $50.80 | 2025 | Pyrukynd |
| Horizon Therapeutics Plc | $48.56 | 2021-2023 | Krystexxa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.33 | 2024-2025 | Xifaxan |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $38.71 | 2025 | Rexulti |
| Preventric Diagnostics, INC. | $35.09 | 2021 | |
| Cranial Technologies, INC | $26.75 | 2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $25.93 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.76 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $23.60 | 2025 | Korlym |
| Dexcom, INC. | $21.86 | 2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $18.68 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.78 | 2022 | |
| Philips North America LLC | $15.53 | 2024 | (Ck7) Extended Holter |
| Otsuka America Pharmaceutical, INC. | $13.16 | 2023 | Rexulti |
| Echosens North America, INC. | $12.23 | 2025 | Fibroscan |
| Pfizer INC. | $11.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Najat George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.